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Abstract
Oncolytic adenoviruses have been safe in clinical trials but the efficacy has been mostly limited. All
published trials have been performed with serotype 5 based viruses. The expression level of the Ad5
receptor CAR may be variable in advanced tumors. In contrast, the Ad3 receptor remains unclear, but is
known to be abundantly expressed in most tumors. Therefore, we hypothesized that a fully serotype 3
oncolytic adenovirus might be useful for treating cancer. Patients exposed to adenoviruses develop high
titers of serotype-specific neutralizing antibodies, which might compromise re-administration. Thus,
having different serotype oncolytic viruses available might facilitate repeated dosing in humans.
Ad3-hTERT-E1A is a fully serotype 3 oncolytic adenovirus controlled by the promoter of the catalytic
domain of human telomerase. It was effective in vitro on cell lines representing seven major cancer
types, although low toxicity was seen in non-malignant cells. In vivo, the virus had anti-tumor efficacy
in three different animal models. Although in vitro oncolysis mediated by Ad3-hTERT-E1A and
wild-type Ad3 occurred more slowly than with Ad5 or Ad5/3 (Ad3 fiber knob in Ad5) based viruses, in
vivo the virus was at least as potent as controls. Anti-tumor efficacy was retained in presence of
neutralizing anti-Ad5 antibodies whereas Ad5 based controls were blocked. In summary, we report
generation of a non-Ad5 based oncolytic adenovirus, which might be useful for testing in cancer
patients, especially in the context of high anti-Ad5 neutralizing antibodies.
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Abstract 
Oncolytic adenoviruses have been safe in clinical trials but efficacy has been mostly limited. All 
published trials have been performed with serotype 5 based viruses. The expression level of the Ad5 
receptor CAR may be variable in advanced tumors. In contrast, the Ad3 receptor remains unclear 
but is known to be abundantly expressed in most tumors. Therefore, we hypothesized that a fully 
serotype 3 oncolytic adenovirus might be useful for treating cancer. Patients exposed to 
adenoviruses develop high titers of serotype specific neutralizing antibodies, which might 
compromise re-administration. Thus, having different serotype oncolytic viruses available might 
facilitate repeated dosing in humans. Ad3-hTERT-E1A is a fully serotype 3 oncolytic adenovirus 
controlled by the promoter of the catalytic domain of human telomerase. It was effective in vitro on 
cell lines representing seven major cancer types, while low toxicity was seen in non-malignant cells. 
In vivo, the virus had anti-tumor efficacy in three different animal models. Although in vitro 
oncolysis mediated by Ad3-hTERT-E1A and wild type Ad3 occurred more slowly than with Ad5 or 
Ad5/3 (Ad3 fiber knob in Ad5) based viruses, in vivo the virus was at least as potent as controls. 
Anti-tumor efficacy was retained in presence of neutralizing anti-Ad5 antibodies while Ad5 based 
controls were blocked. In summary, we report generation of a non-Ad5 based oncolytic adenovirus, 
which might be useful for testing in cancer patients, especially in the context of high anti-Ad5 
neutralizing antibodies. 
Introduction 
Gene therapy and oncolytic viruses are promising ways of treating cancers incurable with current 
therapies. Treatment approaches take advantage of molecular differences between normal and 
tumor cells. Various strategies are currently in clinical development with adenoviruses as the most 
popular vehicle 1, 2. Adenoviruses are useful tools for both gene delivery and oncolytic cell killing. 
In the former approach, E1-deleted, “replication deficient” viruses are typically used, while the 
latter harnesses the cell killing potential of viral replication per se. Typically, viruses are modified 
to retain replication competence in tumor but not normal cells 3. 
 An optimal oncolytic adenovirus would infect and replicate only in cancer cells and 
would be potent enough to kill all cancer cells before the immunological response neutralizes the 
virus. Making certain deletions or adding tissue specific promoters can make the virus more 
selective while adding transgenes can make the approach more potent 4. Nevertheless, in the 
context of advanced tumor masses, it is unlikely that a single round of treatment would eradicate the 
tumor. Although in theory virus replication can proceed as long as there are tumor cells, in practice 
intratumoral barriers limit efficacy 5, 6. Therefore, re-administration of the virus is likely to be 
required for increasing efficacy. A key factor limiting systemic re-administration is the neutralizing 
antibody response induced by the virus 7, 8.  
 More than 50 serotypes of adenoviruses have been identified. Nevertheless, all cancer 
trials utilizing recombinant adenoviruses have featured subgroup C viruses, which in most cases has 
been Ad5. Furthermore, while biological selection has been used to identify a non-Ad5 based 
oncolytic virus 9, and an E1 containing but non-selective Ad11p based virus has been recently 
reported 10, most tumor selective viruses have been based on Ad5. According to previous 
publications, there are several advantages to using serotype chimeric capsids in the context of an 
otherwise serotype 5 virus 11-15. Even though serotype chimerism allows partial escape from pre-
existing neutralizing antibodies against Ad5, and vice versa, the fact that most of the virus capsid is 
still from Ad5 renders the escape incomplete 8. Therefore, it would be advantageous to use a fully 
non-Ad5 virus, especially in the context of high titers of neutralizing antibodies against Ad5 16. 
This situation might arise as a result of natural infection or subsequent to treatment with an Ad5 
based oncolytic virus.  
 In this study, we hypothesised that an oncolytic adenovirus based on serotype 3 could 
be constructed and would allow tumor cell killing. Some candidate receptors for adenovirus 3 have 
been proposed, but these findings have been disputed in other publications and therefore the cellular 
entry of Ad3 remains poorly understood 17-20. Nevertheless, it has been possible to show that the 
receptor(s) most relevant for Ad3 are highly expressed in many cancer cell types 15, 17, 21-25 in 
contrast to the Ad5 receptor CAR which may be frequently downregulated in advanced tumors 13, 
23, 26-28.  
        Wild type Ad3 causes mainly respiratory infections and conjuctivitis in humans 29. The 
complete DNA sequence was reported in 2005 and it has only 62.75% identity with serotype 5. The 
genomic organisation is similar to other human Ads having early and delayed early transcription 
units, including late and major late units 18. 
 In recent decades research on telomeres and telomerases has progressed rapidly. 
Telomerase activation is a critical step in human carcinogenesis, and most human tumors feature 
activity of telomerase. This feature is closely linked with activity of catalytic subdomain hTERT 
promoter, which has been suggested to be active in most human tumors and may therefore be a 
useful tumor specific promoter 30-33.  
 In this study, we constructed the first fully serotype 3 based oncolytic adenovirus 
Ad3-hTERT-E1A. Efficacy analysis revealed oncolytic potency in all tumor cell lines tested, except 
a line known to lack the Ad3 receptor. The virus was attenuated in non-tumor cells. Efficacy was 
also seen in three animal models of human cancer and the virus was not blocked by anti-Ad5 
antibodies. 
Results 
Construction and replication of Ad3-hTERT-E1A  
Following standard cloning procedures, Ad3-hTERT-E1A was rescued and grown to large scale. 
PCR and sequencing was used to confirm the structure of the virus (Fig. 1). Methodology 
established for Ad5 based viruses had to be optimized to account for the slower replication of Ad3 
wild type and Ad3-hTERT-E1A. To estimate functional titer, the usual 10-day cytopathic effect 
assay was not sufficient and therefore we developed a more dynamic progressive infectivity assay 
(Fig. 1c), where cytopathic effect was allowed to develop until the titer plateaued. We believe this 
represents the actual functional titer of the virus.  
 
Oncolytic potency of Ad3-hTERT-E1A on cancer cell lines in vitro 
The ability of Ad3-hTERT-E1A to kill cancer cells in vitro was analyzed by infecting monolayers 
representing seven different tumor types (Fig. 2 and Figure S1). In all malignant cell lines Ad3-
hTERT-E1A showed complete oncolysis while the non-replicative Ad5/3luc1 virus showed no cell 
killing (p<0.05). However, as anticipated based on experience from growing and titering the virus, 
Ad3-hTERT-E1A was somewhat slower than the serotype 5 viruses.  
 
Tumor selectivity of Ad3-hTERT-E1A 
For analyzing tumor selectivity, we infected HUVEC (human umbilical vein endothelial cells) and 
FSH173WE (fibroblasts) with the same viruses and performed cell killing assays (Fig. 3). No cell 
killing was seen at low virus concentrations and at higher doses Ad3-hTERT-E1A was less toxic 
than the control viruses Ad3wt, Ad5wt, Ad5/3-hTERT-E1A, Ad5/3-∆24 (0.1, 1 and 10 VP/cell 
P<0.05). From previous work with Ad5/3 chimeras, we knew that LNM-35/EGFP cannot be 
infected with Ad5/3 and thus may lack the Ad3 receptor 34. Fittingly, no cell killing was seen with 
Ad3-hTERT-E1A or Ad3 wild type. 
 Oncolytic potency in vivo 
We tested the efficacy of Ad3-hTERT-E1A in mice bearing PC-3MM2 prostate cancer xenografts 
(Fig. 4). Ad3-hTERT-E1A was able to reduce tumor growth significantly in comparison to PBS 
injections (P=0.0035). Interestingly, even though the virus was slower than positive controls in 
vitro, there was no difference in efficacy in vivo. In mice with A549 xenografts, the Ad3-hTERT-
E1A group had the smallest tumors from day 17 onwards. At day 17 a borderline difference 
(P=0.051) could be seen comparing Ad3-hTERT-E1A and the PBS. At day 30 Ad3-hTERT-E1A 
had reduced tumor growth significantly (P=0.01) more than Ad5/3-hTERT-E1A, which is known to 
be a highly potent oncolytic adenovirus 35, 36. Therefore, Ad3-hTERT-E1A proved highly potent 
in vivo.  
 
Subcutaneous tumors may not be optimal surrogates of human cancers and therefore we proceeded 
to utilize an orthotopic model featuring intraperitoneally disseminated carcinomatosis induced with 
luciferase expressing SKOV3Luc cells (Figs. 4c,d). Ad3-hTERT-E1A significantly reduced the 
luciferase signal as compared to PBS treated mice (P<0.0001). There was no difference in efficacy 
between the different replication competent viruses. Ad3-hTERT-E1A extended the median 
survival of mice from 34 to 46 days (PBS versus Ad3-hTERT-E1A), which resulted in a significant 
difference in Kaplan-Meier survival analysis (P=0.01). One out of the 7 mice treated with Ad3-
hTERT-E1A survived until the end of the experiment (day 120) and may have been cured as no 
evidence of tumor could be detected in luciferase imaging or autopsy and its behavior was normal. 
 
Neutralization of Ad3-hTERT-E1A by anti-Ad5 antibodies 
Many humans have circulating anti-Ad5-antibodies and they can also become induced as a result of 
treatment with oncolytic adenovirus. Since Ad3-hTERT-E1A is based fully on serotype 3, it might 
be able to escape neutralization by anti-Ad5 antibodies. This was tested in mice with orthotopic 
SKOV3-Luc tumors. Anti-Ad5 antibodies blocked Ad5 wild type (P=0.003, day 21) and the 5/3 
chimeric virus (P=0.03, day 14) (knob from Ad3 but otherwise Ad5) but not Ad3-hTERT-E1A (Fig. 
5).  
 
Discussion 
Oncolytic adenoviruses are promising anti-tumor agents. However, achieving efficacy against 
advanced solid tumors may require multiple rounds of administration. Although efficacy of 
intratumoral injection does not seem to be compromised by neutralizing antibodies 37, metastatic 
disease might well benefit from systemic delivery or from the prolonged systemic dissemination 
which results from intratumoral injection38-40. These, however, are attenuated by high neutralizing 
antibodies titers 7, 8. Therefore, it would be advantageous if a non-Ad5 based oncolytic adenovirus 
would be available for use in patients with high anti-Ad5 neutralizing antibodies titers, or 
previously treated with Ad5 agents.  
 
Currently, little has been published on serotype 3 adenoviruses in the context of gene therapy 18. 
However, a wild type Ad3 virus was studied under normoxic and hypoxic conditions 41. The same 
group recently published ColoAd1, a complex Ad3/Ad11p chimeric virus, which  was made by 
pooling an array of serotypes and then passaging the pools under conditions that invite 
recombination between serotypes 9. These highly diverse viral pools were then placed under 
stringent directed selection to generate and identify potent agents. The authors reported that the 
Ad3/Ad11p chimeric virus was 2-3 orders of magnitude more potent and selective than the parent 
serotypes or the most clinically advanced oncolytic Ad, ONYX-015, in vitro. These results were 
further supported by in vivo and ex vivo studies. However, the safety and efficacy of this agent may 
be difficult to predict due to the complex chimerism involved. In the same publication a direct 
comparison of wild type Ad5 and Ad3 was reported on some normal and tumor cell lines with data 
well in accord to our findings. 
 
We constructed Ad3-hTERT-E1A, which contains the hTERT promoter up-stream of the E1A 
transcription site for tumor specific replication. hTERT is universally expressed in tumors but not 
normal tissues and may therefore be a useful pan-carcinoma promoter 42. In vitro, the virus seemed 
slower in reaching the maximum titer and the functional infectivity assay required 35 days to show 
maximum cytopatic effect. Although both fully Ad3 viruses eventually killed all cancer cells in a 
cytotoxicity assay, they seemed slower than Ad5 based oncolytic agents, including a 5/3 serotype 
chimera. In non-cancer cells, Ad3-hTERT-E1A was less toxic than the control viruses, including 
wild type Ad3. Ad3-hTERT-E1A was not able to kill cells that lack the Ad3 receptor. 
 
Despite being somewhat slower than controls in vitro, Ad3-hTERT-E1A was at least as oncolytic as 
Ad5 and Ad5/3 based controls in vivo. This finding has two interpretations. First, faster replication 
may not automatically mean better tumor control. Slower dissemination might result in fewer 
necrotic or hypoxic areas which can compromise viral penetration. Second, expression of viral 
receptors relevant for replication may not be expressed identically in vitro and in vivo. Ad3-hTERT-
E1A binds to the currently unknown Ad3 receptor. However, this receptor has been proposed to be 
expressed to high degree in tumor cells 15, 17, 21-25, 43. Also, it does not seem to be 
downregulated during carcinogenesis, as proposed for the Ad5 receptor CAR 13, 23, 26-28. 
Identification of the receptor might help in understanding of the behaviour of Ad3-hTERT-E1A. 
 
One potential concern with using the hTERT promoter is toxicity to telomerase positive normal 
tissue stem cells. However, since an hTERT regulated oncolytic adenovirus (based on serotype 5) 
has been safely used in phase 1 trials 44, the promoter may be feasible for human use. Nevertheless, 
Ad3-hTERT-E1A has different tropism than Ad5. In particular, Ad3 based viruses may be able to 
enter stem cell type cells better than Ad5 20, 35, 45, 46. In theory, this might be a safety concern in 
the context of normal tissue stem cells, some of which might be positive for the Ad3 receptor and 
hTERT. However, since most humans have sustained wild type adenovirus type 3 infections 
without detectable symptoms of normal tissue stem cell loss, these cells may have other ways of 
protecting against adenovirus. Also since the mitotic rate of normal stem cells is low, the activity of 
hTERT might be lower compared to aggressive tumors.   
 
 
In summary, we have constructed the first selectively oncolytic adenovirus fully based on serotype 
3. This may also be the first non-Ad5 based oncolytic adenovirus controlled by a tumor specific 
promoter. Efficacy was seen in tumor cell lines and the virus was at least as potent as Ad5 or Ad5/3 
based controls in several murine models of human cancer and the virus was not blocked by anti-
Ad5 antibodies. Further studies are needed to study murine biodistribution and toxicity, prior to 
possible human testing. Eventually, Ad3-hTERT-E1A might be a useful agent for clinical testing in 
patients with anti-Ad5 neutralizing antibodies or previously treated with an Ad5 based agent.  
Materials and Methods 
Cell culture 
293 cells were purchased from Microbix (Toronto, Canada). 293-2v6-11 cells contain an 
ponasteron-inducible E4orf6 region 47. 911-1c11 were kept in 1mg/ml G418 18. SKOV3.ip1 
ovarian adenocarcinoma cell line was obtained from Dr. Price (M. D. Anderson Cancer Center, 
Houston, TX). Firefly luciferin-expressing ovarian adenocarcinoma cell line SKOV3-luc was kindly 
provided by Dr. Negrin (Stanford Medical School, Stanford, CA). PC-3MM2 highly metastatic 
hormone refractory subline of prostate carcinoma was a kind gift of Isaiah J. Fidler (MD Anderson 
Cancer Center, Houston, TX). LNM35/EGFP, a highly lymphogenous metastatic subline of a 
human large cell carcinoma of the lung, was provided by Takashi Takahashi (The Honda Research 
Institute, Japan). The Human Umbilical Vein Endothelial Cells (HUVEC) were bought from Lonza 
(Basel, Switzerland). The following cell lines were obtained from ATCC (Manassas, VA): ACHN 
kidney cell carcinoma, A549 lung adenocarcinoma, FHS173WE human fibroblast cell line, 
HCT116 colorectal carcinoma, CAMA-1 breast adenocarcinoma, PANC-1 pancreatic epithelioid 
carcinoma. All cell lines were cultured under recommended conditions. 
 
Construction of Ad3-hTERT-E1  
For cloning of Ad3-hTERT-E1 three different PCR were performed on Ad3-wt plasmid 
pKSB2Ad3wt 18, two of them to exclude the original TATA-box from Ad3wt sequence. First PCR 
product included left ITR with MluI digestion site until the TATA-box (forward primer: 5’-CAT 
GGT ACC CAA GTG TGT CGC TGT CGA GT-3’, reverse primer 5’-CAT GAT ATC AGC GAT 
CAG CTG ACA CCT AC-3’; adding KpnI site in front and EcoRV site at the end), second started 
directly after the TATA-box until first half of E1A region (forward primer: 5’-CAT GAT ATC 
GTG CCA GCG AGA AGA GTT TT-3’, reverse primer 5’-CAT TCT AGA GCG AGC ACA ATA 
GTT CTT TCA-3’; adding EcoRV site at front and XbaI at the end). A third PCR amplified 1600 
bp of the end of adenovirus type 3 including right ITR. The respectively digested first two PCR 
products around the TATA-box were cloned into KpnI/XbaI digested pUC19 cloning vector 
resulting in pGBAd3E1, including a TATA-box excluded start of Ad3 sequence. hTERT promoter 
derived from pBT255 was digested with KpnI/XhoI, blunted, and cloned in front of the E1 region 
by EcoRV digestion of pGBAd3E1 resulting in pGBAd-3hTERT-E1.  
 
The third PCR product with the end of Ad3 sequence was now cloned into NotI/blunted pShuttle, 
followed by digestion with HindIII, and subsequently cloned into HindIII digested pGBAd3-
hTERT-E1 resulting in pSGBAd3-hTERT-E1 as shuttle vector with end and modified start of 
adenovirus 3 genome. Finally pSGBAd3-hTERT-E1 was digested with XhoI/MscI, resulting in the 
plasmid being opened up in between the modified start and preserved end of adenovirus 3 sequence, 
and homologous recombined with MluI digested and thus backbone-free pKSB2Ad3wt, to reduce 
background due to same resistance gene and achieve a plasmid with Ad3-hTERT-E1 sequence 
(pKGB-Ad3-hTERT-E1).  
 
The recombinant Ad3-hTERT-E1A virus was rescued by transfecting 911-1c11 cells with MluI-
digested pKGB-Ad3-hTERT-E1. Subsequent amplification of a first large Ad3-hTERT-E1A virus 
stock was done in 293-2v6-11 cells, followed by 2nd amplification in A549 cells. All tests done in 
this paper are made with the 2nd virus stock. After amplification the viruses were purified on double 
cesium chloride gradients. The stocks were confirmed not to have serotype 3 wild type or serotype 
5 contamination by PCR. Later the hTERT (295bs) insertion area was controlled to be correct by 
sequencing the purified DNA of the virus. The area was sequenced with ten primers and the 
expected sequence for 1244bps was seen (Fig. 1).  
Other adenoviruses  
Please see table 1 for adenoviruses used in this study.  
 Progressive infectivity assay 
The cells were plated on 96-well plates, 10 000 cells/well and rows were infected the next day by 
lowering dilution from 10-5 to 10-12 of Ad3-hTERT-E1A, each dilution in ten duplicates. Infection 
was done in DMEM, 2% FBS. Plates were observed by microscope and cytopatic effect of the virus 
wells were compared to the mock wells. From the observations pfu/ml was calculated in the similar 
way than in TCID50 (Adeasy manual, Agilent Technologies, Inc. 2008). The media (DMEM, 5% 
FBS) was changed every 4 to 7 days. 
 
In vitro cytotoxicity assays  
Cells were plated at 10 000 cells/well on 96 well plates. The next day, cells in triplicates or 
quadruplicates were infected with the viruses at 0.1 to 100 VP/cell. Infection was done in 2% fetal 
bovine serum (FBS). The plates were regularly observed and the growth media was changed every 
3-5 days. Six to twenty days later, as optimal for each line, cell viability was analyzed with MTS 
assay (Cell Titer 96 AQueous One Solution Cell Proliferation Assay, Promega). MTS analyzes 
were performed on the following days: PC-3MM2 on day 8, A549 on day 17, HCT116 on day 6, 
SKOV3.ip1 on day 18, HUVEC on day 11, FSH174WE on day 13, LNM-35/EGFP on day 10, 
CAMA-1 on day 11, PANC-1 on day 20 and ACHN on day 11. 
 
Animal experiments 
All animal experiments were approved by the Experimental Animal Committee of the University of 
Helsinki and the Provincial Government of Southern Finland. Mice where frequently monitored for 
their health status and euthanized as soon as signs for pain or distress was noticed. For the 
subcutaneus model female NMRI nude mice were used (Charles River, Germany). They were 
ordered at the age of 3-4 weeks and quarantined for 2 weeks. For the intraperitoneal model female 
fox chase SCID mice (Charles River, Germany) were used. They were ordered at the age of 6-7 
weeks and quarantined for 4 months. 
 
Subcutaneous animal experiment 
Mice resieved subcutaneous injections of 2x106 PC-3MM2 or 5x106A549 cells into both flanks. 
After 11 (A549) or 13 (PC-3MM2) days tumors reached injectable size and were treated with 
109VP in 50µl PBS. Controls received PBS only. The injection was repeated after one and two 
weeks. Tumors were measured frequently and the volume was calculated V = L x H2 x 0.52. The 
measured volume before the first treatment was regarded as 100% and the tumor growth was 
compared to this. With the A549 group some of the tumors treated with PBS grew aggressively and 
the mice had to be euthanized after two and a half weeks. 
 
Intraperitoneal animal experiment 
An orthotopic model of peritoneally disseminated ovarian cancer was developed by injecting 5x106 
SKOV3-luc cells intraperitoneally in 300µl of pure DMEM into SCID mice. After three days the 
mice (n=7) were imaged noninvasively and treated intraperitoneally by injecting PBS or 109VP in 
PBS per mouse. The mice were imaged on day 3, 7, 14, 21, 28, 35 and 42 using IVIS 100 
(Xenogen, Alameda, CA, USA) to estimate the number of tumor cells in the mice. For 
bioluminescence imaging, 150mg/kg D-luciferin (Promga, Madison, WI, USA) was injected 
intraperitoneal and captured 10min later with 10s exposure time, 1f/stop, medium binning and open 
filter. During imaging the mice were in isoflurane gas anesthesia. Images were overlaid with Living 
Image 2.50 (Xenogen). Total flux (photons/s) was measured by drawing regions of interest (ROI) 
around the peritoneal area of the mice. Background was subtracted.  
 
Neutralizing antibody experiment 
Anti-Ad5 neutralizing antibodies were produced as reported 8. Briefly, a non-replicative Ad5(GL) 
virus was injected subcutaneously on days 0, 3 and 6 into 16 immunocompetent NMRI mice. A 
month later blood was collected and allowed to clot. The serum (which contains the Ad5 
neutralising antibodies) was then heated to 56C for 40 minutes to inactivate complement and 
frozen.  
In the second phase of the experiment 5x106 SKOV3-luc cells (human ovarian cancer) were 
injected intraperitoneally into SCID mice on day 0 (N=5/group). For treatment of the mice, 109VP 
with and without the Ad5 neutralizing antibody serum was injected intraperitoneally on days 3, 7 
and 14. For each mouse 50ul of serum was mixed with 50ul of PBS containing the virus. The 
number of tumor cells as a function of time was estimated with repeated luciferase imaging of live 
animals as in the intraperitoneal efficacy experiment above.  
  
Statistical analysis 
Nonparametric Mann-Whitney test (SPSS 15.0 for Windows) was used to compare two independent 
samples for all the in vitro and some of the in vivo data. The analysis of tumor size was performed 
using a repeated measures model with PROC MIXED (SAS Ver. 9.1). Models were run with the 
tumor size measurements in the natural metric and log transformed. The effects of treatment group, 
time in days and the interaction of treatment group and time were evaluated by F tests. Curvature in 
the models was tested for by a quadratic term for time. The a priori planned comparisons of specific 
differences in predicted treatment means averaged over time and at the last timepoint were 
computed by t-statistics. For the A549 experiment we compared the groups at 17 and 30 days and 
the PC-3MM2 at 30 days and time-averaged. Survival was evaluated using the Kaplan-Meier 
survival plot with log rank regression (SPSS 15.0 for Windows). For all analyses a two-sided P 
value of <0.05 was deemed statistically significant. 
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Supplementaty material 
Figure S1 
Cell killing assays with CAMA-1 (breast cancer), PANC-1 (pancreas cancer) and ACHN (renal 
cancer) cells. Ad3-hTERT-E1A showed cell killing in all of these cancer types. In all experiments 
Ad3-hTERT-E1A was significantly more efficient than the replication deficient control Ad5/3luc1 
in 100VP/cell (P<0.05). Bars indicate SE. 
 
Figure S2 
In vivo antitumor efficacy of Ad3-hTERT-E1A. A bioluminescence picture taken on day 28. 
 
Figure S3 
An electron microscope picture of the Ad3-hTERT-E1A.  
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Figure legends 
Fig. 1 
(a) Structure of Ad3-hTERT-E1A. The hTERT promoter (295bp) was inserted to replace the 
TATA-box in front of the E1A region of the adenovirus 3. Arrows indicate the sequenced area 
(1244bp). The sequencing confirms that the backbone is adenovirus serotype 3, that the hTERT 
promoter is in the right location and that the promoter is correct.  
(b) Progressive infectivity assay with Ad3-hTERT-E1A. The cells were plated on 96-well plates 
and rows infected by lowering dilution from 10-5 to 10-12 of Ad3-hTERT-E1A, each dilution in ten 
duplicates. Plates were observed by microscope and virus wells were compared to the uninfected 
mock wells. From the observations pfu/ml was calculated in the similar way than in TCID50. The 
media (DMEM, 5% FBS) was changed every 4 to 7 days. The pfu/ml titer plateaus after 30 days, 
suggesting slow replication kinetics for Ad3-hTERT-E1A in vitro. The experiment was performed 
on three cell lines, and twice on A549 cells.  
 
Fig. 2 
Cell killing assays with cancer cell lines. PC-3MM2 (prostate cancer), A549 (lung cancer), HCT116 
(colon cancer) and SKOV3.ip1 (ovarian cancer) cells were used. Ad3-hTERT-E1A showed cell 
killing in all cell lines (P<0.05 versus Ad5/3luc1, the replication deficient control, at 10 VP/cell). 
Ad5wt, Ad5/3-hTERT-E1A and Ad5/3-∆24 killed cells faster than Ad3-based viruses. Bars indicate 
SE. 
 
Fig. 3 
Cell killing assays with non-malignant and Ad3 receptor deficient cells. HUVEC (human umbilical 
vein endothelial cells) and FSH173WE (fibroblasts) were used to represent non-tumor cells. Ad3-
hTERT-E1A did not differ from replication deficient Ad5/3luc1 at low doses and killed 
significantly less cells than positive controls Ad3wt, Ad5wt, Ad5/3-∆24 at 0.1, 1 and 10 VP/cell 
(P<0.05). From previous studies 34 it was known that LNM-35 (lung cancer) cells lack the Ad3 
receptor. Ad3wt and Ad3-hTERT-E1A did not show any cytotoxicity on these cells. Bars indicate 
SE. 
 
Fig. 4 
In vivo efficacy of Ad3-hTERT-E1A 
(a) PC-3MM2 (highly metastatic hormone refractory prostate carcinoma) tumors were grown in 
nude mice. 109 VP was injected into each tumor weekly for a total of three injections and tumors 
were measured every 2-3 days. Tumors treated with Ad3-hTERT-E1A grew more slowly than PBS 
treated tumors (P=0.0035). Bars indicate SE. 
(b) Similar data were seen in mice with A549 (lung cancer) tumors although the PBS group had to 
be terminated early due to large tumor size. On day 17 a difference bordering on significance 
(P=0.051) was seen comparing PBS and Ad3-hTERT-E1A. Also, on day 30 Ad3-hTERT-E1A was 
found significantly (P=0.01) better than Ad5/3-hTERT-E1A, a highly potent positive control. Bars 
indicate SE. 
(c) Luciferase expressing SKOV3-luc ovarian cancer cells were grown intraperitoneally in SCID 
mice. A single intraperitoneal 109 VP virus injection was performed and the the number of tumor 
cells as a function of time was estimated with repeated luciferase imaging of live animals. A 
significant difference in the luciferase signal was seen between all virus treated groups and the PBS 
group (P<0.0001), and there were no differences between virus groups. In this experiment Ad5wt 
could be included as an additional positive control. Bars indicate SE.  
(d) In survival analysis, all virus treated groups survived longer than the PBS group (P≤0.01). The 
only long term survivor from the experiment was one out of 7 mice from the Ad3-hTERT-E1A 
group. It was healthy and tumor free in imaging and autopsy at 120 days, when the experiment was 
ended. 
Fig. 5 
In vivo Ad5 neutralising antibody experiment.  
A non-replicative Ad5(GL) virus was injected subcutaneously on days 0, 3 and 6 into 
immunocompetent NMRI mice. A month later serum containing the Ad5 neutralising antibodies 
were collected, heated and frozen. In the second phase of the experiment 5x106 SKOV3-luc cells 
(human ovarian cancer) were injected intraperitoneally into SCID mice on day 0. 109VP diluted in 
PBS, with or without the Ad5 neutralizing antibody serum, was then injected intraperitoneally on 
days 3, 7 and 14. The number of tumor cells as a function of time was estimated with repeated 
luciferase imaging of live animals. A significant difference in luciferase signal was seen between 
Ad5wt mixed with serum and Ad5wt without serum (P=0.003, day 21) and between Ad5/3-hTERT-
E1A with and without serum (P=0.03, day 14). Ad3-hTERT-E1A was not blocked by the anti-Ad5 
serum. Bars indicate SE.  
  
Table 1. Adenoviruses used in this study 
Virus name Backbone 
serotype 
Fiber 
knob 
serotype 
E1A Ratio 
(VP/pfu) 
Reference 
Ad5 wt 5 5 Wild type 19 ATCC 
(Ad300 wt 
strain) 
Ad5/3-hTERT-E1A 5 3 Controlled by hTERT 
promoter (mediates selectivity 
to telomerase active cells) 
10 35 (Named 
here Ad5/3-
hTERT-∆gp) 
Ad5/3-∆24 5 3 24bp deletion (mediates 
selctivity to p16/Rb pathway 
mutant tumor cells) 
22 48 
Ad5/3luc1 5 3 Deleted (makes virus 
replication deficient) 
5 15 
Ad3 wt 3 3 Wild type 9 18 
Ad3-hTERT-E1A 3 3 Controlled by hTERT 
promoter (mediates selectivity 
to telomerase active cells) 
9 This article 
 
 
 





